CN115335381A - 白细胞介素-1受体相关激酶的双功能降解剂及其治疗用途 - Google Patents

白细胞介素-1受体相关激酶的双功能降解剂及其治疗用途 Download PDF

Info

Publication number
CN115335381A
CN115335381A CN202180015953.3A CN202180015953A CN115335381A CN 115335381 A CN115335381 A CN 115335381A CN 202180015953 A CN202180015953 A CN 202180015953A CN 115335381 A CN115335381 A CN 115335381A
Authority
CN
China
Prior art keywords
compound
alkyl
optionally substituted
radical
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180015953.3A
Other languages
English (en)
Chinese (zh)
Inventor
威利·索朗·帕尔默
杰弗里·吴
希拉·齐普费尔
科雷姆·奥兹博亚
达利亚·维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinruisi Biopharmaceutical Co ltd
Gilead Sciences Inc
Original Assignee
Xinruisi Biopharmaceutical Co ltd
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xinruisi Biopharmaceutical Co ltd, Gilead Sciences Inc filed Critical Xinruisi Biopharmaceutical Co ltd
Publication of CN115335381A publication Critical patent/CN115335381A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180015953.3A 2020-02-19 2021-02-19 白细胞介素-1受体相关激酶的双功能降解剂及其治疗用途 Pending CN115335381A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062978635P 2020-02-19 2020-02-19
US62/978,635 2020-02-19
PCT/US2021/018710 WO2021168197A1 (en) 2020-02-19 2021-02-19 Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof

Publications (1)

Publication Number Publication Date
CN115335381A true CN115335381A (zh) 2022-11-11

Family

ID=74870905

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180015953.3A Pending CN115335381A (zh) 2020-02-19 2021-02-19 白细胞介素-1受体相关激酶的双功能降解剂及其治疗用途

Country Status (9)

Country Link
US (1) US12528814B2 (https=)
EP (1) EP4107158A1 (https=)
JP (1) JP7815127B2 (https=)
KR (1) KR20220155295A (https=)
CN (1) CN115335381A (https=)
AU (1) AU2021224923A1 (https=)
CA (1) CA3165009A1 (https=)
TW (1) TW202140489A (https=)
WO (1) WO2021168197A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118406019A (zh) * 2024-07-02 2024-07-30 苏州源起材料科技有限公司 一种噻唑化合物生物医药砌块的合成方法
WO2024245331A1 (zh) * 2023-05-30 2024-12-05 上海汇伦医药股份有限公司 三并环类化合物、其制备方法和应用
WO2024245443A1 (zh) * 2023-06-01 2024-12-05 标新生物医药科技(上海)有限公司 基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用
CN119119080A (zh) * 2024-09-06 2024-12-13 上海信诺维生物医药有限公司 一种irak4的蛋白降解剂
WO2025036451A1 (zh) * 2023-08-15 2025-02-20 潘普洛纳生物科技（深圳）有限公司 靶向irak蛋白抑制或降解的化合物及其应用
WO2025149070A1 (zh) * 2024-01-10 2025-07-17 甘李药业股份有限公司 一种新型靶向白细胞介素1受体关联激酶4(irak4)的蛋白降解嵌合体化合物的合成及其应用
CN120757537A (zh) * 2025-09-09 2025-10-10 广东省科学院动物研究所 Protac降解剂及其应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US11739101B2 (en) 2020-05-06 2023-08-29 Nurix Therapeutics, Inc. Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
FI4367118T3 (fi) * 2021-08-18 2025-04-09 Nurix Therapeutics Inc Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö
EP4430052A1 (en) 2021-11-10 2024-09-18 Nurix Therapeutics, Inc. Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
AU2022405474A1 (en) * 2021-12-08 2024-07-18 Gluetacs Therapeutics (Shanghai) Co., Ltd. E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications
WO2023186069A1 (zh) * 2022-03-31 2023-10-05 石药集团中奇制药技术（石家庄）有限公司 一类白介素-1受体相关激酶4的双功能嵌合体杂环化合物及其制备方法、药用组合物和用途
CN119630802A (zh) 2022-04-12 2025-03-14 建新公司 Irak4调节剂用于基因疗法的用途
CN117164583A (zh) * 2022-05-20 2023-12-05 斯迈旭(苏州)生物科技有限公司 一种靶向irak4蛋白降解的化合物及其应用
WO2025126115A1 (en) 2023-12-13 2025-06-19 Beigene Switzerland Gmbh Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligands and methods of use
WO2026050190A1 (en) * 2024-08-27 2026-03-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Smyd3 protacs for the treatment of hpv-negative squamous cell carcinoma

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254533A (zh) * 2012-01-13 2014-12-31 百时美施贵宝公司 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
CN107849039A (zh) * 2015-06-24 2018-03-27 百时美施贵宝公司 经杂芳基取代的氨基吡啶化合物
CN108026099A (zh) * 2015-06-24 2018-05-11 百时美施贵宝公司 经杂芳基取代的氨基吡啶化合物
US20190192668A1 (en) * 2017-12-26 2019-06-27 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20200048261A1 (en) * 2018-08-13 2020-02-13 Gilead Sciences, Inc. PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES
WO2020036986A1 (en) * 2018-08-13 2020-02-20 Gilead Sciences, Inc. Thiadiazole irak4 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US7041298B2 (en) 2000-09-08 2006-05-09 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US7030112B2 (en) 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
CA2663091A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
US9464326B2 (en) 2012-03-22 2016-10-11 University Of Maryland, Baltimore Total and phosphorylated IL-1 receptor-associated kinase-1 and IL-1 receptor-associated kinase-4 as a biomarker for cancer progression and chemotherapy resistance
TW201609693A (zh) 2014-01-03 2016-03-16 必治妥美雅史谷比公司 雜芳基取代之菸鹼醯胺化合物
AU2015247817C1 (en) 2014-04-14 2022-02-10 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
US10487329B2 (en) 2015-10-29 2019-11-26 Children's Hospital Medical Center Methods and compositions for the treatment of head and neck cancer
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2018071606A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP3532164A4 (en) 2016-10-28 2020-10-07 Children's Hospital Medical Center TREATMENT OF IRAQ ASSOCIATED DISEASES ACTIVATED
BR112019015484A2 (pt) 2017-01-31 2020-04-28 Arvinas Operations Inc ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
WO2018232288A1 (en) 2017-06-16 2018-12-20 Genentech, Inc. Diagnostic and therapeutic methods for irak4-mediated disorders and conditions
US11065231B2 (en) * 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2019103196A1 (ko) 2017-11-24 2019-05-31 엘지전자 주식회사 무선 통신 시스템에서 빔을 리포팅하는 방법 및 장치
WO2019160915A1 (en) 2018-02-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Irak degraders and uses thereof
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
US20200038513A1 (en) 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP4038066A1 (en) 2019-10-01 2022-08-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
US11820781B2 (en) 2019-12-04 2023-11-21 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
WO2021180103A1 (en) 2020-03-11 2021-09-16 Beigene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
MX2022016061A (es) 2020-06-17 2023-02-02 Kymera Therapeutics Inc Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos.
WO2021255212A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Braf degraders
CA3217892A1 (en) 2021-05-03 2022-11-10 Joel Mcintosh Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
FI4367118T3 (fi) 2021-08-18 2025-04-09 Nurix Therapeutics Inc Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254533A (zh) * 2012-01-13 2014-12-31 百时美施贵宝公司 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
CN107849039A (zh) * 2015-06-24 2018-03-27 百时美施贵宝公司 经杂芳基取代的氨基吡啶化合物
CN108026099A (zh) * 2015-06-24 2018-05-11 百时美施贵宝公司 经杂芳基取代的氨基吡啶化合物
US20190192668A1 (en) * 2017-12-26 2019-06-27 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20200048261A1 (en) * 2018-08-13 2020-02-13 Gilead Sciences, Inc. PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES
WO2020036986A1 (en) * 2018-08-13 2020-02-20 Gilead Sciences, Inc. Thiadiazole irak4 inhibitors

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024245331A1 (zh) * 2023-05-30 2024-12-05 上海汇伦医药股份有限公司 三并环类化合物、其制备方法和应用
WO2024245443A1 (zh) * 2023-06-01 2024-12-05 标新生物医药科技(上海)有限公司 基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用
WO2025036451A1 (zh) * 2023-08-15 2025-02-20 潘普洛纳生物科技（深圳）有限公司 靶向irak蛋白抑制或降解的化合物及其应用
WO2025149070A1 (zh) * 2024-01-10 2025-07-17 甘李药业股份有限公司 一种新型靶向白细胞介素1受体关联激酶4(irak4)的蛋白降解嵌合体化合物的合成及其应用
CN118406019A (zh) * 2024-07-02 2024-07-30 苏州源起材料科技有限公司 一种噻唑化合物生物医药砌块的合成方法
CN118406019B (zh) * 2024-07-02 2024-09-20 苏州源起材料科技有限公司 一种噻唑化合物生物医药砌块的合成方法
CN119119080A (zh) * 2024-09-06 2024-12-13 上海信诺维生物医药有限公司 一种irak4的蛋白降解剂
CN120757537A (zh) * 2025-09-09 2025-10-10 广东省科学院动物研究所 Protac降解剂及其应用
CN120757537B (zh) * 2025-09-09 2026-01-06 广东省科学院动物研究所 Protac降解剂及其应用

Also Published As

Publication number Publication date
KR20220155295A (ko) 2022-11-22
JP2023514323A (ja) 2023-04-05
WO2021168197A1 (en) 2021-08-26
US20230142629A1 (en) 2023-05-11
EP4107158A1 (en) 2022-12-28
US12528814B2 (en) 2026-01-20
CA3165009A1 (en) 2021-08-26
TW202140489A (zh) 2021-11-01
AU2021224923A1 (en) 2022-08-11
JP7815127B2 (ja) 2026-02-17

Similar Documents

Publication Publication Date Title
CN115335381A (zh) 白细胞介素-1受体相关激酶的双功能降解剂及其治疗用途
JP7603609B2 (ja) アンドロゲン受容体を標的に分解する二官能性キメラ複素環式化合物及びその使用
JP7440940B2 (ja) Ｐｌｋ１の選択的分解誘導化合物
JP7208142B2 (ja) Ｒｈｏキナーゼ阻害剤としてのチロシンアミド誘導体
KR101921486B1 (ko) ＰＡＲＰ억제제인 4Ｈ-피라졸로[1,5-ａ]벤즈이미다졸 화합물의 아날로그
JP6479850B2 (ja) Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体
CN115836072A (zh) Kras g12c蛋白的抑制剂和其用途
JP2024523657A (ja) ホスファターゼ分解剤の合成及び応用
TWI886406B (zh) 介白素-1受體相關激酶之雙官能降解劑及其治療用途
CN112424188A (zh) 作为parp7抑制剂的哒嗪酮
KR20190055260A (ko) 안드로겐 수용체의 표적 분해용 화합물 및 방법
CN107074812B (zh) 取代的嘧啶化合物
TW202308655A (zh) 膦醯衍生物及其組合物和藥學上的應用
HK40083579A (en) Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
JP2026074171A (ja) インターロイキン－１受容体関連キナーゼの二機能性分解剤およびその治療的使用
CN120957981A (zh) 基于2,4-二苯胺嘧啶的Aurora-A激酶选择性降解诱导化合物
HK40115438A (zh) 造血祖细胞激酶的双功能降解剂及其治疗用途
WO2026039844A1 (en) Stat6 degraders and uses thereof
JP2025536323A (ja) 縮合二環式化合物ならびにＭｅｒ阻害剤およびＡｘｌ阻害剤としてのその使用
CN104024261B (zh) 咪唑并哒嗪化合物
HK40107816A (zh) 白介素-1受体相关激酶的双官能降解物及其治疗用途
HK40053673B (zh) 一种btk抑制剂环衍生物及其制备方法和药学上的应用
HK40055574B (zh) 用於治疗自身免疫性疾病的六氢-1h-吡嗪幷[1，2- a]吡嗪化合物
HK1192227B (en) Thiazolopyrimidine compounds
HK40009464A (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40083579

Country of ref document: HK